Login / Register


Password: [Lost?]

New User? Click here for your FREE subscription

Healthcare Professionals
Healthcare Professionals Healthcare Professionals

Follow Us

NEWS-Line on Twitter NEWS-Line on Facebook NEWS-Line on Google+ NEWS-Line on LinkedIn NEWS-Line on Pinterest

Healthcare Conferences &
Educational Opportunities

Jan. 31 - Feb. 2

TAPA 2020 Annual CME Conference

Texas Academy of Physician Assistants

March 6 - 08

2020 Western Regional Occupational Therapy Spring Symposium

OT Associations of CA, ID, HI, AZ, NV, NM, UT

April 21 - 24

Atlanta CME Conference

Skin, Bones, Hearts & Private Parts

June 9 - 12

Destin CME Conference

Skin, Bones, Hearts & Private Parts

July 10 - 12

ASHA Connect 2020

American Speech-Language-Hearing Association

More Events

Yale Cancer Center study shows using checkpoint inhibitors promising for patients with myeloid cancers | NEWS-Line for Healthcare Professionals

Yale Cancer Center study shows using checkpoint inhibitors promising for patients with myeloid cancers


Yale Cancer Center study shows using checkpoint inhibitors promising for patients with myeloid cancers

New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show promising results using checkpoint inhibitors for patients with myeloid cancers. The study was presented at the 61st American Society of Hematology (ASH) meeting in Orlando, Florida. The annual conference is attended by an international audience of more than 25,000 hematology professionals.

Amer Zeidan, MBBS, MHS, associate professor of medicine (hematology) at YCC, is leading the research study using the chemotherapy drug azacitidine. Azacitidine is a standard treatment for patients with acute myeloid leukemia (AML) who are unfit for intensive chemotherapy as well as those with higher-risk myelodysplastic syndromes (MDS). Pre-clinical research had suggested that azacitidine might prove more effective when combined with a checkpoint inhibitor drug such as durvalumab, which inhibits the PD-L1 protein that cancer cells may use to hold off immune system attacks. This theory was tested by Zeidan and colleagues in a large, international randomized phase 2 clinical trial of first-line treatments for both groups of patients, which compared azacitidine alone versus azacitidine combined with durvalumab.

“The final results showed no significant improvement in response rate or survival of patients with the combination therapy in either cohort,” said Zeidan. “But this study was the first randomized trial of immune checkpoint inhibition, a form of immune therapy which provided impressive results in patients with some forms of advanced solid tumors, in patients with myeloid malignancies.” Zeidan added the trial is also expected to yield additional laboratory results that improve the understanding of immune changes in these blood cancers and might inform the design of future trials with these agents.

About Yale Cancer Center and Smilow Cancer Hospital

Yale Cancer Center (YCC) is one of only 51 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in Connecticut. Cancer treatment for patients is available at Smilow Cancer Hospital through 13 multidisciplinary teams and at 14 Smilow Cancer Hospital Care Centers in Connecticut. Smilow Cancer Hospital is accredited by the Commission on Cancer, a Quality program of the American College of Surgeons. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.

Source: Yale University

Share This!

Healthcare Jobs


Baptist Health

Medical Laboratory Scientist

Baptist Health


Baptist Health

X-Ray Tech

Foothill Family Clinic
Salt Lake City, Utah

Nurse Practitioner, Clinical Instructor, Pediatrics

Stony Brook University
Stony Brook,

Program Director and Associated Professor in the Doctor of Physical Therapy Program

Burlington, VT

More Jobs
(Dismiss) Thank you for visiting NEWS-Line! Please sign up, login, or follow us on your favorite social networks
to receive custom tailored eNews, job listings, and educational opportunities for your specific profession.